Cardiomagnil, 150 mg+30.39 mg 100 pcs

Indications

Angina

– Unstable angina and stable angina;

– Prevention of recurrent myocardial infarction;

– Prevention of recurrent transient ischemic attack (TIA) and recurrent ischemic stroke in patients who have previously suffered a stroke;

– Prevention of thrombotic complications after surgeries and invasive vascular interventions (such as coronary artery bypass surgery, carotid endarterectomy, arteriovenous bypass, angioplasty and stenting of coronary arteries, angioplasty of carotid arteries).

Active ingredient

Acetylsalicylic acid, Magnesium hydroxide

Composition

One tablet contains

The active ingredients:

Acetylsalicylic acid ……………………………………………75 mg / 150 mg

Magnesium hydroxide ……………………………………………………….15.2 mg / 30.39 mg

Excipients: corn starch, microcrystalline cellulose, magnesium stearate, potato starch; coating: hypromellose (methylhydroxypropylcellulose 15), propylene glycol, talc.

.

How to take, the dosage

Tablets should be swallowed whole with water. If desired, the tablet may be broken in half, chewed or pre-mashed.

Unstable and stable angina pectoris
1 tablet of Cardiomagnil containing ASA at a dose of 75-150 mg, once daily.

Prevention of recurrent myocardial infarction
1 tablet of Cardiomagnol containing ASA at a dose of 75-150 mg, once daily.

Prevention of recurrent transient ischemic attack (TIA) and recurrent ischemic stroke in patients who have previously had a cerebral circulation disorder 1 tablet of Cardiomagnil containing ASA at a dose of 75-150 mg, once daily.

Prevention of thrombotic complications after operations and invasive vascular interventions (such as aortocoronary bypass, carotid endarterectomy, arteriovenous bypass, angioplasty and stenting of the coronary< brbr> arteries, carotid angioplasty) 1 tablet of Cardiomagnil containing ASA in a dose of 75-150 mg, once a day.

Special patient groups

Patients with impaired renal function
Cardiomagnanil is contraindicated in patients with severe renal impairment. Caution should be exercised when using Cardiomagnil in patients with impaired renal function because acetylsalicylic acid may increase the risk of renal failure and acute renal failure (see
Specific information.

Patients with impaired hepatic function
The drug Cardiomagnil is contraindicated in patients with severe hepatic impairment. Caution should be exercised when using the drug Cardiomagnesil in patients with hepatic impairment.

Children
Safety and efficacy of the use of acetylsalicylic acid + [magnesium hydroxide] in children under the age of 18 years has not been established. There are no data.

The use of the drug Cardiomagnil in patients under 18 years is contraindicated.

Take the drug only according to the indications, the method of administration and in the doses specified in the instructions.

Interaction

Simultaneous use of Cardiomagnil with methotrexate may increase hematological toxicity of methotrexate due to decreased renal clearance and its displacement from plasma proteins binding. Use with methotrexate in a dose greater than 15 mg per week is contraindicated. Administration with methotrexate in dose less than 15 mg per week is possible with special caution in case if the benefit to the patient exceeds the risk.

Concomitant use of the drug with other NSAIDs containing salicylates in high doses shows an increased risk of ulcerogenic effects and gastrointestinal bleeding.

When used concomitantly, ASK increases the effect of the following drugs:

– methotrexate by reducing renal clearance and displacing it from binding to proteins

– heparin and indirect anticoagulants by impairing platelet function and displacing indirect anticoagulants from binding to proteins

/p>

– thrombolytic and anti-aggregant and anticoagulant drugs

– digoxin due to decrease of its renal excretion

– Hypoglycemic oral agents (sulfonylurea derivatives) and insulin due to the hypoglycemic properties of ASA at high doses and displacing sulfonylurea derivatives from plasma proteins

– Valproic acid due to its displacement from protein binding

When used concomitantly (for one day) with metamizole and some NSAIDs (including ibuprofen and naproxen) antagonism is noted with respect to irreversible inhibition of platelet function due to the action of ASA.

The clinical significance of this effect is unknown. Combination of ASA with metamizole or NSAIDs (including ibuprofen or naproxen) in patients at high risk of cardiovascular disease is not recommended because of possible reduction of cardioprotective effects of ASA.

When taking ASA in combination with ethanol (alcohol) an increased risk of gastrointestinal mucosal damage and prolongation of bleeding time due to mutual enhancement of ASA and ethanol effects is noted.

Asc attenuates the effects of uricosuric agents (benzbromaron) due to competitive tubular elimination of uric acid.

Asc increases the elimination of salicylates, systemic glucocorticosteroids (GCS) weaken their effects.

The antacids and colestiramine reduce absorption of the drug.

The concomitant use of ASA with selective serotonin reuptake inhibitors may increase the risk of upper gastrointestinal bleeding due to possible synergistic effects.

When concomitant use of diuretics with ASA in high doses, a decrease in glomerular filtration rate due to decreased renal prostaglandin synthesis has been noted.

When angiotensin-converting enzyme inhibitors (ACE) are combined with high doses of ASA, a decrease in glomerular filtration rate as a result of inhibition of prostaglandins that have a vasodilator effect is noted. In addition, a weakening of antihypertensive effect of ACE inhibitors has been noted.

If you are taking the drugs listed above or other drugs (including over-the-counter medications), talk to your doctor before taking this medicine.

Special Instructions

The drug should be used after prescribing by a doctor.
ASK may provoke bronchospasm, as well as cause attacks of bronchial asthma and other hypersensitivity reactions. Risk factors are a history of bronchial asthma, hay fever, nasal polyposis, chronic respiratory diseases, as well as allergic reactions to other drugs (e.g., skin reactions, itching, urticaria).
ASA can cause bleeding of varying severity during and after surgical procedures. Several days before the planned surgical intervention, the risk of bleeding should be assessed in comparison with the risk of ischemic complications in patients taking low-dose ASA. If the risk of bleeding is significant, ASA administration should be temporarily stopped.
Combination of ASA with anticoagulants, thrombolytics and antiplatelet agents is accompanied by an increased risk of bleeding.
ASK in low doses may provoke development of gout in predisposed patients (those with decreased excretion of uric acid).
Combination of ASK with methotrexate is accompanied by increased frequency of side effects from the hematopoietic organs.
High doses of ASA have hypoglycemic effect that should be borne in mind when prescribing it to patients with diabetes mellitus receiving oral hypoglycemic agents and insulin.
If systemic glucocorticosteroids (GCS) and salicylates are used concomitantly, it should be remembered that during treatment the concentration of salicylates in blood is reduced, and after withdrawal of systemic glucocorticosteroids (GCS) an overdose of salicylates is possible.
Metamizole and some NSAIDs (including ibuprofen, naproxen) may weaken the inhibitory effect of ASA on platelet aggregation. Patients taking ASA and planning to take methamisole or NSAIDs should discuss this with the attending physician (see
section “Interaction with other medicinal products”).
Exceeding the dose of ASA above the recommended therapeutic doses is associated with the risk of gastrointestinal bleeding.
Long-term use of low doses of ASA as an aggregate therapy should be observed with caution in elderly patients due to the risk of gastrointestinal bleeding.
Simultaneous use of ASA with alcohol increases the risk of gastrointestinal mucosal damage and prolongation of bleeding time.
In patients with impaired renal function or in patients with circulatory disorders due to renal artery disease, chronic heart failure, hypovolemia, extensive surgery, sepsis or
cases of massive bleeding, the drug Cardiomagnil should be used with caution because ASA may increase the risk of acute renal failure and renal function disorders.
In severe forms of glucose-6-phosphate dehydrogenase deficiency, ASK may cause hemolysis and hemolytic anemia. Factors that may increase the risk of hemolysis are fever, acute infections, and high doses of the drug.
Drugs containing ASA should not be used in children and adolescents to treat viral infections with or without fever without medical advice. In certain viral diseases, particularly influenza A, influenza B and chickenpox, there is a risk
of developing Reye’s syndrome, a very rare but life-threatening illness that requires immediate medical attention. The risk may be increased if ASA is used as concomitant therapy, but a causal link has not
been confirmed. Irreducible vomiting in the above diseases may be a symptom of Ray’s syndrome.
When using the drug alone, the maximum time and recommended doses should not be exceeded. It is recommended to consult a physician in case of absence of reduction or in case of aggravation of symptoms.

Influence on the ability to drive vehicles, mechanisms
During treatment with ASA drugs, care should be taken when driving vehicles and engaging in potentially dangerous activities that require increased concentration and rapid psychomotor reactions.

Synopsis

Filmed film-coated tablets containing 75 mg/15.2 mg of acetylsalicylic acid and magnesium hydroxide, respectively: film-coated tablets, white, stylized “heart” shape Filmed film-coated tablets containing 150 mg/30.39 mg of acetylsalicylic acid and magnesium hydroxide, respectively: film-coated tablets, white, oval shape with a break on one side.

Contraindications

Hypersensitivity to ASA, excipients of the drug and other NSAIDs, cerebral hemorrhage; susceptibility to bleeding (vitamin K deficiency, thrombocytopenia, hemorrhagic diathesis); bronchial asthma, induced by taking salicylates and NSAIDs; complete or incomplete combination of bronchial asthma, recurrent polyposis of the nose and sinuses and intolerance to acetylsalicylic acid or other NSAIDs, including COX-2 inhibitors (including a history); gastrointestinal erosive-ulcerative lesions (acute phase); gastrointestinal bleeding; severe hepatic impairment; severe renal failure (creatinine clearance less than 30 ml/min); chronic heart failure III-IV functional class according to NYHA classification; Pregnancy (I trimester, II trimester more than 20 weeks, and III trimester of pregnancy); breastfeeding period; glucose-6-phosphate dehydrogenase deficiency; concomitant use with methotrexate (more than 15 mg per week); children under 18 years of age.

With caution

. In gout, hyperuricemia, history of gastrointestinal ulcers or gastrointestinal bleeding, impaired liver function, impaired renal function, bronchial asthma, hay fever, nasal polyposis, hypersensitivity to analgesics, anti-inflammatory drugs, anti-rheumatic drugs, and allergic reactions to other substances, in anticipated surgical procedures (including minor, such as tooth extraction) In the second trimester of pregnancy up to 20 weeks.

Caution should be exercised with concomitant therapy with the following drugs:

Methotrexate at a dose of less than 15 mg per week; anticoagulant, thrombolytic, or other antiaggregant agents; methamisole and NSAIDs (including ibuprofen, naproxen), digoxin, oral hypoglycemic drugs (sulfonylurea derivatives) and insulin, valproic acid, ethanol, selective serotonin reuptake inhibitors).

If you have any of the above conditions, you should consult your doctor before using the drug.

Side effects

Criteria for evaluating the frequency of adverse reactions: very common (≥1/10), common (≥1/100, < 1/10), infrequent (≥1/1000, < 1/100), rare (≥1/10000, < 1/1000); very rare (< 1/10000); frequency unknown – cannot be estimated based on available data.